A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Acute Myeloid Leukemia (AML)
Status:
RECRUITING
Trial end date:
2029-08-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with Acute Myeloid Leukemia (AML) with a mutation in the NPM1 or KMT2A gene.